Grifols acquires minority stake in US biotech firm

7 July 2017

Grifols (GRLS: MC), a Spain-based manufacturer of plasma-derived drugs, is set to acquire a minority stake in a US biopharmaceutical company based in San Francisco (California) specialized in the discovery and development of pre-clinical biotherapeutics.

Under the terms of the deal, Grifols will pay $35 million in cash for a 43.96% share in GigaGen, which focuses its activity on discovering new biological treatments by using antibodies derived from millions of cells within immune repertoires.

Among other applications, its innovative technological platform enables identifying and analyzing the genetic diversity of B cells to convert them into polyclonal recombinant antibodies (biotherapeutics) that improve outcomes for patients with severe diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK